Literature DB >> 8003851

Effects of a corticosteroid, budesonide, on alveolar macrophage and blood monocyte secretion of cytokines: differential sensitivity of GM-CSF, IL-1 beta, and IL-6.

M Linden1, R Brattsand.   

Abstract

Down-regulation of cytokine production in activated human blood monocytes (BMs) and alveolar macrophages (AMs) can be achieved in vitro by treatment with corticosteroids. The inhibition of cytokine secretion by corticosteroids may have important therapeutic consequences in e.g. asthma. However, relatively little is known about possible differences in the sensitivity of different cytokines to corticosteroid treatment. Homologous BMs and AMs were obtained from six healthy volunteers. Secretion of interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in the cultures of lipopolysaccharide (LPS) stimulated adherent BMs and AMs was analysed using specific immunoassays. Sensitivity of the IL-1 beta, IL-6, and GM-CSF secretion to the in vitro treatment with a synthetic corticosteroid, budesonide, was compared. BMs and AMs displayed significant differences in both cytokine secretion and susceptibility to regulation by budesonide. When added to the BM cultures concomitantly with LPS, budesonide suppressed IL-1 beta and IL-6 only partially (to 30% of the control level). In contrast, GM-CSF release in these cultures was almost totally inhibited by budesonide (> or = 10(-8) M). The IC50 for inhibition of the GM-CSF secretion was as low as 2 x 10(-10) M. In the AM cultures, budesonide had very little effect on IL-1 beta and IL-6 secretion (inhibition to 80% and 60% of control levels, respectively), while GM-CSF secretion was suppressed to 20% of control by budesonide concentrations > or = 10(-7) M.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8003851     DOI: 10.1006/pulp.1994.1004

Source DB:  PubMed          Journal:  Pulm Pharmacol        ISSN: 0952-0600


  9 in total

1.  PCT-233, a novel modulator of pro- and anti-inflammatory cytokine production.

Authors:  E Y Bissonnette; L-I Proulx; V Turmel; R Drouin; M Purcell
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

2.  Glucocorticoid sensitivity of lipopolysaccharide-stimulated chronic obstructive pulmonary disease alveolar macrophages.

Authors:  J Armstrong; C Sargent; D Singh
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

3.  Is low dose inhaled corticosteroid therapy as effective for inflammation and remodeling in asthma? A randomized, parallel group study.

Authors:  Melissa Baraket; Brian G G Oliver; Janette K Burgess; Sam Lim; Gregory G King; Judith L Black
Journal:  Respir Res       Date:  2012-02-02

4.  Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients.

Authors:  Nikolai V Kuznetsov; Arezou Zargari; Alexander W Gielen; Oliver D von Stein; Eugen Musch; Ragnar Befrits; Robert Lofberg; Petra von Stein
Journal:  BMC Gastroenterol       Date:  2014-04-23       Impact factor: 3.067

Review 5.  Glucocorticoids-All-Rounders Tackling the Versatile Players of the Immune System.

Authors:  Cindy Strehl; Lisa Ehlers; Timo Gaber; Frank Buttgereit
Journal:  Front Immunol       Date:  2019-07-24       Impact factor: 7.561

6.  Autoimmune pulmonary alveolar proteinosis developed during immunosuppressive treatment in polymyositis with interstitial lung disease: a case report.

Authors:  S Sato; K Akasaka; H Ohta; Y Tsukahara; G Kida; E Tsumiyama; K Kusano; T Oba; T Nishizawa; R Kawabe; H Yamakawa; M Amano; H Matsushima; T Takada
Journal:  BMC Pulm Med       Date:  2020-04-06       Impact factor: 3.317

7.  Outcome of corticosteroid administration in autoimmune pulmonary alveolar proteinosis: a retrospective cohort study.

Authors:  Keiichi Akasaka; Takahiro Tanaka; Nobutaka Kitamura; Shinya Ohkouchi; Ryushi Tazawa; Toshinori Takada; Toshio Ichiwata; Etsuro Yamaguchi; Masaki Hirose; Toru Arai; Kentaro Nakano; Takahito Nei; Haruyuki Ishii; Tomohiro Handa; Yoshikazu Inoue; Koh Nakata
Journal:  BMC Pulm Med       Date:  2015-08-12       Impact factor: 3.317

8.  Long-Term Outcome of Treatment with Topical Corticosteroids for Severe Dry Eye Associated with Sjögren's Syndrome.

Authors:  Hyun Ho Jung; Yong Sok Ji; Mi Sun Sung; Kyung Keun Kim; Kyung Chul Yoon
Journal:  Chonnam Med J       Date:  2015-04-14

9.  Characterization of epithelial IL-8 response to inflammatory bowel disease mucosal E. coli and its inhibition by mesalamine.

Authors:  Sreedhar Subramanian; Jonathan M Rhodes; C Anthony Hart; Ben Tam; Carol L Roberts; Shirley L Smith; John E Corkill; Craig Winstanley; Mumtaz Virji; Barry J Campbell
Journal:  Inflamm Bowel Dis       Date:  2008-02       Impact factor: 5.325

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.